All In Biotech

Investigational drug · Phase 2

GNS561

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Cholangiocarcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

5

Any phase or sponsor naming "GNS561"

First trial start

2023

Aug 21, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "GNS561", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Cholangiocarcinoma

Approved drugs for the same conditions: Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "GNS561" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 16 on PubMed

Also in development for Cholangiocarcinoma

  • tinengotinibTT-00420Phase 36 trials

    TransThera Sciences (Nanjing), Inc. · Prostate Cancer (CRPC), Cholangiocarcinoma, Hepatocellular Carcinoma (HCC)

  • [18F]FAPI-74 PETPhase 33 trials

    SOFIE · Esophageal Cancer, Gastric Cancer (GC), Gastroesophageal Junction

  • CTX-009Phase 32 trials

    Compass Therapeutics · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer

  • GV20-0251Phase 23 trials

    GV20 Therapeutics · Endometrial Carcinoma (EC), Squamous Head and Neck Carcinoma, pMMR/MSS Adenocarcinoma of the Colon or Rectum

  • certepetideCEND-1, LSTA1Phase 21 trial

    Lisata Therapeutics, Inc. · Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma

  • CGT4859Phase 21 trial

    Cogent Biosciences, Inc. · Intrahepatic Cholangiocarcinoma (Icc), Cholangiocarcinoma, Other Solid Tumors, Adult

  • E7090Phase 21 trial

    Eisai · Cholangiocarcinoma

  • gavo-celPhase 21 trial

    TCR2 Therapeutics · Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.